Forward-looking statements

Historical statements herein reflect published or presented data and or Levomecor Inc. documents, contracts and data. Statements not historical in nature are forward-looking statements and may be identified by the use of words and phrases such as “if”, “may”, “expects”, “anticipates”, “believes”, “will”, “will likely result”, “will continue”, “plans to”, “potential”, “promising”, and similar expressions. These statements are based on Levomecor current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the statements, including the potential for Levomecor’s product candidates to progress, including the potential for Phase 3 esmethadone data to continue to deliver positive results supporting further development, potential for clinical trials to deliver statistically and/or clinically significant evidence of efficacy and/or safety, failure of top-line results to accurately reflect the complete results of the trial, failure of planned or ongoing preclinical and clinical studies to demonstrate expected results, potential failure to secure FDA agreement on the regulatory path for esmethadone or other Levomecor assets or that clinical results will be acceptable to the FDA, failure to secure adequate drug supply, and the other risk factors. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Levomecor undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be considered a complete list.